inVentiv Clinical Solutions Revenue and Competitors
Estimated Revenue & Valuation
- inVentiv Clinical Solutions's estimated annual revenue is currently $11.9M per year.
- inVentiv Clinical Solutions's estimated revenue per employee is $201,000
Employee Data
- inVentiv Clinical Solutions has 59 Employees.
- inVentiv Clinical Solutions grew their employee count by 5% last year.
inVentiv Clinical Solutions's People
Name | Title | Email/Phone |
---|
inVentiv Clinical Solutions Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is inVentiv Clinical Solutions?
At inVentiv Clinical Solutions (iCS), our mission is to be the alternative to traditional clinical outsourcing for the biopharmaceutical industry, allowing clients the greatest control and flexibility through unmatched access to the highest quality clinical resources. iCS provides clients with a variety of flexible options to meet their clinical trial objectives, including outsourcing of one or several functions associated with the clinical trial process, expert clinical staffing and recruitment, and creating strategically resourced work groups. Our solutions are designed to increase efficiency and accelerate results. iCS is headquartered in Houston, Texas, with offices throughout the globe.
keywords:N/AN/A
Total Funding
59
Number of Employees
$11.9M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.7M | 59 | 5% | N/A |
#2 | $13M | 59 | 16% | N/A |
#3 | $12.9M | 59 | -31% | N/A |
#4 | $9.6M | 59 | 5% | N/A |
#5 | $17.3M | 59 | -11% | N/A |